Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by longterm56on Jan 05, 2018 8:17pm

149 Views

Post# 27294889

RE:Who is this guy?

I find this post rather annoying. If you don't "know the name of the guy", why would you label him a bad investor for selling shares when he did. Have you not considered he is a real person with personal reasons for needing to sell????? Why would you judge him if you don't know the circumstances!!!

Certainly not very "smart", smartmichel!!!

- LT

smartmichel wrote:
There were 160,000 shares sold today. I don't know the name of the guy who sold his positions today but he didn't sell at end of ast june at $8.72. At this time, TH was:

1. At 6 months of PDUFA for Ibalizumab, it is now at 89 days max;
2. At an indeterminated time for Europe news and is now 6 months sooner and ''in advance of the plan'' as CEO said..
3. At an indeterminated time for a third drug but now at 6 months sooner for that and ''We have a guy on that'' as CEO said recently at a lunch.
4. With Egrifta sales at a $800,000 pace a week and now at around $1M (as SPCEO posted).
5. With F4 formulation on an undeterminated time of results release and now at the same situation but 6 months sooner of this milestone;
6. Not interested to list on NASDAQ this year (as CFO respond at last inverstor's day last winter, 'but we have not decided for next year'). -as Candide said, not in fact important for trading and SP- but for US analysts coverage and serious targets

I don't know the name of the seller today but if he will eventually post on this bord, his nickname will not be Smartsomebody.

Smartmichel